Memorial Sloan-Kettering’s Green Team, a committee established in 2009 to identify opportunities to reduce waste and conserve resources, effectively reduced energy costs in operating rooms by disabling air exchanges when the rooms are not in use.
People with certain cancers enrolled in clinical trials survive longer, not necessarily from the treatment itself but potentially because those enrolled are better off to begin with, according to new research. MSKCC’s Colin Begg is quoted.
Adam Cohen, Memorial Sloan-Kettering’s Assistant General Counsel and Manager of Immigration Services, commented on a report that found that more than 40 percent of the cancer researchers at America’s top cancer institutes are immigrants.
Hematologist-oncologist Sergio Giralt was featured on this special episode of 20/20 that took viewers on a journey inside Good Morning America co-host Robin Roberts’s fight against myelodysplastic syndrome. Robin received a stem cell transplant to treat her disease at Memorial Sloan-Kettering.
Good Morning America co-host Robin Roberts discussed her return to the program after receiving a stem cell transplant at Memorial Sloan-Kettering with hematologist-oncologist Sergio Giralt, who led her treatment team. Her nurses were also featured on the program.
The Breakthrough Prize in Life Sciences – a new award established by Art Levinson, Sergey Brin, Anne Wojcicki, Mark Zuckerberg, Priscilla Chan, and Yuri Milner – was awarded to physician-scientist Charles Sawyers.
Visible Ink founder Judith Kelman discussed the Memorial Sloan-Kettering program she runs that connects patients with experienced writers, editors, and teachers to help them tell their stories in writing.
Medical oncologist Michael Morris commented on a study that found that men with high-risk prostate cancer treated with only 18 months of hormone therapy live just as long as those treated for a standard 36 months.
IBM, WellPoint, and Memorial Sloan-Kettering Cancer Center have announced what they say are the first commercially developed applications based on IBM’s Watson technology. They include an advanced clinical decision support system for oncologists, and tools designed to accelerate and streamline the prior authorization process at health plans.
Medical oncologists Mark Kris and Larry Norton and cancer biologist Joan Massagué discussed a revolution currently taking place in cancer care – tailoring treatments for specific individuals based on their tumor’s molecular makeup.